News
News

Forbion’s portfolio company Akarna Therapeutics Ltd acquired by Allergan plc

in portfolio news

Forbion Capital Partners (“Forbion”), one of the leading Dutch Venture Capital firms investing in world-class healthcare technologies, today announced the acquisition of its portfolio company Akarna by Allergan plc. Allergan obtains rights to AKN-083, Akarna’s lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.

Under the terms of the agreement, Allergan acquired Akarna for an upfront cash payment of $50million and success-based development, regulatory and sales milestones.

“Akarna is one of our most recent investments in the portfolio of FCF III, the fund we closed in April of this year. This rapid exit is a testimony to our ability to select the most promising young companies in ‘hot’ areas like NASH”, stated Marco Boorsma, Partner at Forbion and responsible for the deal.

Akarna’s other investors include New Science Ventures, LLC, a New York-based venture capital firm and Third Point Ventures, the emerging technology investment arm of Third Point. LLCMoelis & Company LLC acted as financial advisor to Akarna. Wilson Sonsini Goodrich & Rosati LLP acted as legal counsel to Akarna.

Subscribe